The US Food and Drug Administration (FDA) has approved several TLR agonists for cancer treatment, such as BCG (a primarily TLR2/4 agonist) for bladder noninvasive transitional cell carcinoma, AS04 (a TLR4 agonist) for cervical cancer, and imiquimod (a TLR7 agonist) for superficial basal cell carcinoma [137]. Here, TLR4 is linked to cancer.